Blood protein ApoB linked to suicidal thoughts, study and genetic analysis suggest

A Heart-Disease Protein Is Linked to Suicidal Thoughts — but Genetics Refuse to Confirm a Causal Link

For decades, psychiatrists have toyed with an odd hypothesis: that the fats circulating in our blood might whisper something about the state of our minds. The evidence has been messy, contradictory, and easy to dismiss. Now a study published in the open-access journal Annals of General Psychiatry adds a striking new character to that story: apolipoprotein B, the protein that ferries cholesterol through the bloodstream and gives cardiologists their favorite gauge of heart attack risk. In an analysis of 6,520 American adults, researchers report that people with higher levels of ApoB were significantly more likely to report recent suicidal thoughts, even after accounting for age, sex, race, income, body mass index, smoking, drinking, diabetes, and hypertension. Yet when the same team turned to genetics to ask whether ApoB actually causes suicidal ideation, the answer came back negative, leaving behind an intriguing correlation, a tantalizing biological puzzle, and no simple explanation.

The stakes of the question are hard to overstate. Suicide claims hundreds of thousands of lives worldwide each year, ranks as the second leading cause of death among young people, and places a heavy burden on families and health systems. Suicidal ideation — thoughts of self-harm or the feeling that death would be preferable — is among the strongest predictors of eventual suicidal behavior, which makes its early detection a central goal of prevention science. The World Health Organization has set an ambitious target of reducing suicide mortality by one-third by 2030, but the most established risk factors, from sociodemographic hardship to major depressive disorder, are notoriously difficult to modify or to catch in time to act. That gap has pushed researchers toward biological markers: measurable, potentially modifiable, and ideally detectable in a routine blood draw. Lipids have long been recurring candidates, with decades of studies asking whether low cholesterol raises suicide risk — and yielding results that never quite replicated.

ApoB is, at first glance, an unlikely suspect for a psychiatric investigation. It is the core structural protein of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) particles, the lipid-carrying packages implicated in atherosclerosis and heart disease. Because every one of these particles carries exactly one ApoB molecule, measuring ApoB effectively counts the total number of cholesterol- and triglyceride-transporting particles in the blood — a metric many cardiologists consider a more faithful gauge of atherosclerotic cardiovascular risk than LDL cholesterol concentration alone. Synthesized mainly by the liver and small intestine, ApoB’s day job is delivering lipids to peripheral tissues. But in recent years it has begun surfacing in psychiatric literature as well: serum ApoB has been linked to depression and to the cognitive deficits observed in depressed patients, and lipid metabolism is increasingly recognized as a genuine player in brain function, with the potential to influence neuroinflammation, oxidative stress, and the stability of the blood-brain barrier. Earlier studies on ApoB and suicidality, however, had pointed in conflicting directions, some implicating low ApoB levels and others finding no link at all.

To probe the question systematically, a team in China led by corresponding authors Huqiang Dong of Ningxia Medical University and Hongping Cheng of Hubei University of Medicine mined the National Health and Nutrition Examination Survey (NHANES), a nationally representative, biennial assessment of the health and nutritional status of the U.S. population. From 29,902 individuals enrolled in the 2011–2016 cycles, the researchers excluded anyone younger than 20, anyone lacking suicidal-ideation or ApoB measurements, and anyone with incomplete covariate data, leaving 6,520 adults with a mean age of 49.7 years, split almost evenly between men and women. ApoB concentrations were measured in venous blood samples with standardized immunoassays — a turbidimetric assay on a Roche Cobas 6000 analyzer in the 2015–2016 cycle and a nephelometric assay on a Siemens ProSpec analyzer in 2013–2014 — with a lower limit of detection of 25.0 mg/dL and strict quality-control procedures. Suicidal ideation was captured by item nine of the Patient Health Questionnaire-9 (PHQ-9), which asks whether, in the past two weeks, respondents have “often had thoughts of self-harm or thought that death would be better.” Any answer other than “not at all” was counted as suicidal ideation.

The statistical picture that emerged was strikingly consistent. Treating ApoB as a continuous variable, the team built three logistic regression models of increasing adjustment, and the positive association with suicidal ideation survived all of them, holding at P = 0.0463 in the fully adjusted model. Split into tertiles, participants in the middle ApoB group had 56 percent higher odds of suicidal ideation than those in the lowest group (odds ratio 1.56, 95% confidence interval 1.11–2.21, P = 0.0112), while those in the highest tertile showed roughly 48 percent higher odds (odds ratio 1.48, 95% confidence interval 1.04–2.12, P = 0.0312). A trend test across tertiles was significant in every model. To test for non-linearity, the researchers fitted a generalized additive model with a smooth term for ApoB; the fit was significant (P = 0.0109), but the effective degrees of freedom of the smooth term hovered near one — statistical evidence that the relationship was essentially linear: more ApoB, more risk, with no hidden threshold.

The most provocative result came from the subgroup analyses. Across strata of race, education, marital status, body mass index, hypertension, and diabetes, the ApoB–ideation association held steady, with no significant interactions. But when the sample was stratified by smoking status, the association sharpened markedly among smokers, and the interaction test returned P = 0.034 — statistical shorthand for evidence that smoking modifies the relationship. The authors advance two complementary explanations. Biologically, smoking drives chronic low-grade neuroinflammation, flooding the nervous system with inflammatory mediators that could amplify any pro-inflammatory effect of ApoB-rich lipoproteins in the brain and, over time, reshape the circuits that govern emotional regulation. Behaviorally, cigarettes are frequently used as a coping mechanism for negative emotions and stress, a pattern that entangles nicotine dependence with psychological distress and, epidemiologically, with suicidal tendencies. In smokers, the ApoB signal may simply be louder.

Correlation, however, is not causation, and observational studies of lipids are haunted by confounding and reverse causation — depression itself reshapes diet, metabolism, and lipid profiles. To probe causality, the team deployed Mendelian randomization, a technique that exploits the random shuffling of genes at conception as a natural experiment: genetic variants robustly associated with higher ApoB serve as proxies for lifelong exposure, and because they are inherited randomly and fixed before illness develops, they are largely immune to the confounding that plagues observational data. The researchers drew their instruments from a genome-wide association study (GWAS) of 233 blood metabolites conducted by Karjalainen and colleagues on up to 120,241 participants across 33 European cohorts, quantified with high-throughput nuclear magnetic resonance metabolomics. Outcome data came from the UK Biobank, where a GWAS of suicidal ideation in 365,819 participants of European descent was run with SAIGE, a generalized linear mixed model built to handle case-control imbalance. After stringent quality control — linkage-disequilibrium clumping at r² < 0.001, removal of rare variants, harmonization of effect alleles, and screening for pleiotropic outliers with Radial MR and MR-PRESSO — 116 single nucleotide polymorphisms survived as instruments, together explaining 11.33 percent of the variance in ApoB, with F-statistics ranging from 30.03 to 1040.20, far beyond the threshold for weak-instrument bias.

The verdict was null. The primary inverse-variance weighted analysis, which combines the per-variant Wald ratios into a single causal estimate, yielded an odds ratio of 1.24 (95% CI 0.90–1.71, P = 0.181) for the effect of ApoB on suicidal ideation. Four complementary methods converged: the generalized summary-data-based MR approach (GSMR), which additionally performs a HEIDI-outlier test, produced an odds ratio of 1.23 (P = 0.207); the robust adjusted profile score method (MR-RAPS), designed to tolerate pleiotropy and weak instruments, gave 1.22 (P = 0.238); the maximum likelihood method and the constrained maximum likelihood approach with model averaging and Bayesian information criterion (cML-MA-BIC) both returned 1.24. Sensitivity analyses were clean across the board: Cochran’s Q detected no heterogeneity, the MR-Egger intercept test and the MR-PRESSO global test found no horizontal pleiotropy, and leave-one-out analysis showed that no single variant dominated the pooled estimate. An MR Steiger test confirmed the instruments pointed in the correct causal direction, from ApoB toward suicidal ideation rather than the reverse.

Crucially, a post-hoc power analysis indicated that the MR study had 80 percent power to detect a causal odds ratio of 1.35 or larger, given the 116 instruments, the 11.33 percent of ApoB variance explained, and the 365,819-participant outcome GWAS — meaning the null result most likely reflects a genuine absence of strong causality rather than a study too underpowered to see the effect. That leaves the observational association demanding a biological story, and the authors sketch three. First, ApoB-laden lipoproteins are tied to neuroinflammation and oxidative stress, and ApoB itself has been shown to bind enolase-1 and aggravate inflammation; chronic low-grade inflammation is a well-replicated correlate of suicidal behavior. Second, hyperlipidemia is associated with increased permeability of the blood-brain barrier, raising the possibility that ApoB-associated particles entering the brain could provoke localized inflammatory responses and disrupt mood regulation. Third, lipoprotein metabolism intersects with cholesterol synthesis and utilization, which sustain synaptic membrane fluidity and receptor function — disturbances of which can destabilize neurotransmitter signaling.

The study’s limits are acknowledged candidly. The NHANES data are cross-sectional, so the association cannot establish temporal sequence; unmeasured confounders, or the metabolic fingerprints of mental illness itself, could still explain the pattern. The MR analysis, for all its rigor, cannot fully escape caveats about weak instruments, residual pleiotropy, and population stratification, and both the NHANES and GWAS samples derive from U.S. and European populations, constraining generalizability to other ancestries. Still, the work’s strengths — a nationally representative sample, triangulation across two fundamentally different methods, and exhaustive sensitivity testing — make it a substantive contribution. Its practical upshot is twofold: ApoB may deserve attention as a correlate worth tracking in suicide-risk research, particularly among smokers, and the biology linking lipid transport to suicidal thinking likely runs through indirect pathways — inflammation, barrier integrity, and cholesterol-dependent synaptic signaling — that genetic instruments for circulating ApoB alone cannot capture. Longitudinal and mechanistic studies, the authors conclude, must now determine whether ApoB is a genuine player in suicide risk or a metabolic bystander standing close to the fire.